{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Caribou Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"CRBU"},"Address":{"label":"Address","value":"2929 7TH STREET,SUITE 105, BERKELEY, California, 94710, United States"},"Phone":{"label":"Phone","value":"+1 510 982-6030"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies."},"CompanyUrl":{"label":"Company Url","value":"https://www.cariboubio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Rachel E. Haurwitz","title":"President, Chief Executive Officer & Director"},{"name":"Steven B. Kanner","title":"Chief Scientific Officer"},{"name":"Timothy P. Kelly","title":"Chief Technology Officer"},{"name":"Tina Albertson","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}